0.59
-0.0132(-2.19%)
Currency In USD
| Previous Close | 0.6 |
| Open | 0.61 |
| Day High | 0.66 |
| Day Low | 0.55 |
| 52-Week High | 4.32 |
| 52-Week Low | 0.53 |
| Volume | 10.3M |
| Average Volume | 2.22M |
| Market Cap | 5.37M |
| PE | -0.16 |
| EPS | -3.64 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 1.02 |
| Change | -0.01 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of September 17, 2025 at a share price of $0.589. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.21 as of September 17, 2025 at a share price of $0.589.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
GlobeNewswire Inc.
3 hours ago
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using F
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
GlobeNewswire Inc.
Sep 05, 2025 12:45 PM GMT
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
GlobeNewswire Inc.
Aug 25, 2025 1:00 PM GMT
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-21